19.07.2011 • News

Novartis Posts Higher Q2 Profit

Novartis reported second-quarter net income of $2.73 billion or $1.13 per share versus $2.44 billion or $1.06 per share in the year-ago quarter.
Core net income for the quarter increased to $3.56 billion or $1.48 per share from $2 77 billion or $1.20 per share in the previous year.
Quarterly sales climbed to $14.92 billion from $11.72 billion in the prior year.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.40 per share on revenues of $14.42 billion for the quarter. Analysts' estimates typically exclude special items.

Joseph Jimenez, chief executive officer of Novartis, commented, "We achieved strong sales growth of 19% in constant currencies and margin improvement of 0.4 percentage points in U.S. dollars. We further demonstrated the success of our R&D strategy with four major approvals and two filings in the second quarter. Our diversified healthcare portfolio, focused on high growth segments, is enabling us to generate superior results."

 

Company

Novartis Pharma GmbH

Roonstr. 25
90429 Nürnberg

Company contact







From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read